Sanofi raises 2024 profit outlook due to strong Q2 sales of Dupixent, Beyfortus, and Altuviiio.
Sanofi raised its 2024 profit outlook due to strong Q2 demand for asthma drug Dupixent and better-than-expected sales of new products, including Beyfortus and Altuviiio. Q2 sales grew 10.2%, with Dupixent sales increasing 29.2% to €3.3bn. Sanofi now expects stable 2024 earnings per share, an improvement from its previous forecast of a low single-digit percentage drop. The company's shares rose 2.9% following the announcement.
July 25, 2024
3 Articles